Hester Biosciences Q1 FY27: Standalone PAT up 88%, Consolidated PAT up 459%
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported Q1 FY27 results. Standalone revenue rose 14% to INR 726.60M and PAT jumped 88% to INR 147.11M, driven by 48% growth in Poultry Healthcare. Animal Healthcare fell 50% due to government tender delays. Consolidated revenue declined 8% to INR 772.44M, but PAT surged 459% to INR 967.32M, boosted by a one-time exceptional gain of INR 853.49M from Gates Foundation loan amendment at Hester Africa.
Solid standalone results with margin expansion. Consolidated PAT jump is from a one-time accounting gain, not core operations. Watch Animal Healthcare.